The standard of cancer care fails the majority of patients who are then left with no alternative treatment plan. As a result, 50-80% of cancer patients are in no position to survive their cancer. Given the breadth of cancer drugs on the market today, this is simply unacceptable.
Genomic Expression developed the OneRNA® Platfrom to change this. The OneRNA® test can analyze 20,000 mRNAs from one patient sample to identify the most effective treatment for that patient. In fact, the OneRNA® test has been clinlically vallidated in breast and ovarian cancers, and is considered superior compared to traditional DNA panel diagnostics.
SHARE:
Ovarian cancer is one of the toughest cancers to treat, and overcoming it can be a real challenge. Right now, treatment options are mostly a combination of surgery and chemotherapy, with newer targeted therapies helping some patients. Unfortunately, most women with ovarian cancer face a recurrence within 18-24 months. When the cancer comes back—especially if it becomes platinum-resistant and stops responding to standard chemotherapy—treatment options become even more limited and less effective.
That’s why finding better treatments is more important than ever. New strategies are urgently needed to discover drugs—whether existing ones or those still in development—that can make a real difference for every woman facing recurrent ovarian cancer.
There is hope! The OneRNA® Platform developed by Genomic Expression is an exciting new clinical tool designed to individualize cancer treatment. By analyzing 20,000 mRNA markers from a single patient sample, it helps identify the most effective treatment options for each individual. This breakthrough technology has been clinically validated in breast and ovarian cancer, achieving an impressive diagnostic yield of nearly 100%— that means treatment options for all patients are identified.
A huge improvement compared to the 26% yield from traditional methods. With innovations like this, the future of cancer treatment is becoming more effective and truly individualized.
The OneRNA® Platform is a fully developed diagnostic service, ready to launch as a powerful tool for gynecological oncologists. Performed in Genomic Expression’s clinical lab, it’s designed to help individualize treatment for ovarian cancer patients.
Genomic Expression’s next steps include:
Genomic Expression’s founders have personally dealt with cancer and are excited about the impact this could have and are committed to bringing better, more tailored treatment solutions to women facing ovarian cancer.
The funds raised through this campaign will make a huge difference. They’ll be used to support the sales and marketing efforts needed to raise awareness about the OneRNA® Platform and reach more patients. Specifically, these funds will go towards:
We aim to scale revenue to service more patients and hospitals and become more independent of additional funding. We intend to partner with hospitals and hire a CBO that has a strong network and a proven track record in closing companion diagnostic deals with pharma and biotech companies. We already have interest from a potential distributor who specializes in community oncology hospitals, which is a great step forward for our plans.
We’ve raised $6.5M in grants and $1.7M in seed funding, and generated lifetime revenue of $4.5M. We’re also continuing to file for more grants in 2025, aiming for over $6.5M in additional funding. Plus, we have some exciting strategic partnerships lined up that we expect will close in 2025. Things are moving forward in a big way!
The OneRNA® Platform has already shown its potential as a life-saving tool, helping to identify individualized drug combinations for cancer patients. This is especially critical for those facing cancers with limited treatment options and no clear path to a cure—like women battling recurrent ovarian cancer. Right now, 5-year survival rates are only 30-40% for platinum-sensitive disease and just 10-15% for platinum-resistant cases.
https://www.genomicexpression.com/
“Early Detection” by Bruce Ratner and Adam Bonislawski: Clinical RNA sequencing in oncology: where are we? By Gitte Pedersen, CEO of Genomic Expression, and Norman Friedland co-founder, of FullSky Partners.
Published patent application PCT/US2022/028582: “Identification and design of cancer therapies based on RNA sequencing”
CEO & Co-Founder
MSc, BA Business, company builder with a mission to improve health and sustainability. RNA enthusiast. Advised a number of small and medium-sized biotech companies as well as the Danish Ministry of Foreign Affairs, bringing in +$1B deals to Danish Biotech companies. Won numerous prices, awards and raised $8M in grants. Worked at Novo Nordisk in several management positions and brought multiple products to market worldwide.
Chief Scientific Officer & Co-Founder
Postdoc in genetics from Copenhagen University. Serial entrepreneur and inventor of groundbreaking novel enzymatic nucleic acid chemistries. Created proof of concept for several new life science technologies, such as novel sequencing and sequencing sample prep technologies and DNA and RNA synthesis technologies. Have filed and issued patents in USA, Europe, and Canada. Worked at Chr. Hansen, where he invented novel genetic engineering methods, and TAG Copenhagen, where he implemented DNA sequencing and synthesis services.
Chief Medical Officer
$100 donated by Bert Nieves
